Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational, Secondary Data Collection Study to Describe Acalabrutinib Treatment Outcomes in Chronic Lymphocytic Leukemia Patients in Real-life Setting in Romania

NCT06170671 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06170671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06170671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational, Secondary Data Collection Study to Describe Acalabrutinib Treatment Outcomes in Chronic Lymphocytic Leukemia Patients in Real-life Setting in Romania
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
December 13, 2023
Completion date
September 30, 2028
Enrollment
250 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia